Other languages CureVac N.V. Deutsche Boerse AG

Equities

5CV

NL0015436031

Market Closed - Deutsche Boerse AG Other stock markets 01:48:19 2024-06-28 pm EDT			5-day change	1st Jan Change
3.094 ^EUR	-0.83%		+0.85%	-19.43%

Jun. 24	CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board	CI
May. 28	CureVac, GSK Begin Dosing in Phase 2 Study for Seasonal Influenza Vaccine Candidate	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

CureVac N.V. Approves the Appointment of Birgit Hofmann as a Member of the Supervisory Board	Jun. 24
CureVac Announces Voting Results of General Meeting	Jun. 24
CureVac Announces Voting Results of General Meeting	Jun. 24
Öl- und Bankentitel schwach - EZB wirft Schatten voraus	Jun. 04
XETRA-SCHLUSS/DAX schwächer - der Bund macht Kasse	Jun. 04
CureVac N.V. Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK	May. 28
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK	May. 28
CureVac gibt Impfung des ersten Teilnehmers in einer Phase-2-Studie zur saisonalen Grippe bekannt; Entwicklung in Zusammenarbeit mit GSK	May. 28
CureVac N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 23
CUREVAC : Significant cash drain in the Q1	May. 23
Starke Einkaufsmanager verderben Nvidia-Laune	May. 23
CureVac veröffentlicht Finanzergebnisse für das erste Quartal 2024 und informiert über seine Geschäftsentwicklung	May. 23
CureVac veröffentlicht Finanzergebnisse für das erste Quartal 2024 und informiert über seine Geschäftsentwicklung	May. 23
CUREVAC : A missed opportunity	May. 02
CureVac N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 25
CureVac Begins Early Stage Portion of Investigational Vaccine Trial	Apr. 24
Höherer Verlust: Impfstoffhersteller Curevac will effizienter werden	Apr. 24
Biotechfirma CureVac verkleinert sich und streicht 150 Stellen	Apr. 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	Apr. 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza; Development in Collaboration with GSK	Apr. 24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

CUREVAC : Significant cash drain in the Q1

May 23, 2024 at 03:49 pm EDT